Cogent Biosciences (COGT) Share-based Compensation (2017 - 2026)

Cogent Biosciences' Share-based Compensation history runs 10 years deep, the most recent figure standing at $16.9 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 68.94% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $38.3 million (down 5.02% YoY), while the FY2025 annual figure was $46.1 million, up 15.95% from the prior year.
• Share-based Compensation was $16.9 million for Q1 2026 at Cogent Biosciences, up from $1.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $16.9 million in Q1 2026 to a low of $1.1 million in Q4 2025.
• Historically, Share-based Compensation has averaged $8.1 million across 5 years, with a median of $8.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 134.42% in 2022, then slumped 88.97% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $5.0 million in 2022, then soared by 75.72% to $8.9 million in 2023, then increased by 12.72% to $10.0 million in 2024, then slumped by 88.97% to $1.1 million in 2025, then soared by 1437.09% to $16.9 million in 2026.
• The last three Share-based Compensation figures came in at $16.9 million (Q1 2026), $1.1 million (Q4 2025), and $10.6 million (Q3 2025), per Business Quant data.